Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018285 | 0.83 | TUBB4A (0.39) | ERN1MGLL | |
| SCHEMBL22132828 | 0.82 | ERN1 (0.38) | FGFR1FGFR3ERN1MGLL | |
| SCHEMBL20981734 | 0.80 | ACHE (0.38) | FGFR1FGFR3ACHEERN1 | |
| SCHEMBL6715101 | 0.78 | CA2 (0.50) | MGLL | |
| SCHEMBL22132793 | 0.77 | ACHE (0.45) | FGFR1FGFR3ACHEERN1 | |
| SCHEMBL16010451 | 0.77 | CYP3A4 (0.37) | ACHEMGLL | |
| SCHEMBL16016845 | 0.75 | MGLL (0.35) | MGLL | |
| SCHEMBL25334615 | 0.74 | ACHE (0.42) | FGFR1FGFR3ACHE | |
| SCHEMBL22315356 | 0.74 | ACHE (0.42) | FGFR1FGFR3ACHE | |
| SCHEMBL31061930 | 0.74 | ACHE (0.42) | FGFR1FGFR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433190-B | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-116514806-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3925960-B1 | FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-111225907-B | Process for preparing benzothien-2 yl boric acid/borate | 拜耳制药股份公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115433190-A | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-11-10 | — | — | US | disclosed |
| WO-2022166469-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20220177475-A1 | FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| EP-2817311-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013124316-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013124316-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013087647-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087578-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR3 3/4885ACHE 4852/4885 |
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BPGM, BRCA1, BRAP | FGFR1 836/4885FGFR3 1202/4885ACHE 4734/4885 |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | STK25, CDK5, JAK2 | FGFR1 216/4885FGFR3 580/4885ACHE 4872/4885 |
| US-20150031676-A1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF | STK25, JAK2, PTK2B | FGFR1 186/4885FGFR3 533/4885ACHE 4876/4885 |
| US-20220177475-A1 | FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885FGFR3 4/4885ACHE 4862/4885 |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, NR2C2, FGFR1 | FGFR1 3/4885FGFR3 4/4885ACHE 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.